Skip to main content
ARCT logo

ARCT · Arcturus Therapeutics Holdings Inc.

Track ARCT — free
$7.45 -0.15 (-1.97%) At close · Nov 20
Market Cap
$214.73M
Shares
28.82M
Volume · Nov 20 602K Avg daily vol (3M) 883.08K

Price & Indicators

 

Key stats

Close
$7.45
Fri 20 Nov
Open
$7.40
Fri 20 Nov
Average volume, 30 days
650K
shares a session
Short interest
5.4M
18.8% of shares · 7.4 days to cover
Day range
$7.31$7.73
Open $7.40 Close $7.45
52-week closing range
$5.53$16.93
Close $7.45 56.0% under the high
Short volume, last session
55%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

Mar 2, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 16
Current report 8-K
Meiji invests $50.0 million at 80% premium

Arcturus sold 2,466,395 shares to Meiji for $50.0 million at an 80% premium, alongside an ARCT-154 license and a nonbinding MOU covering pandemic preparedness in Japan.

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure
3 source passages
On November 16, 2026, Arcturus Therapeutics Holdings Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Meiji Seika Pharma Co., Ltd. (“Meiji”). Pursuant to the terms of the Purchase Agreement, the Company sold to Meiji an aggregate of 2,466,395 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), for an aggregate purchase price of $50.0 million. The purchase price represents a premium of 80% to the average closing price of the Common Stock over the 30 trading days through and including November 11, 2026. Concurrently with the Purchase Agreement, Arcturus Therapeutics, Inc., a wholly owned subsidiary of the Company (“Arcturus”), and Meiji entered into a license agreement relating to the application of ARCT-154 technology for an undisclosed therapeutic area. Meiji will be responsible for development and commercialization at its cost. The Company and Meiji also entered into a non-binding memorandum of understanding (the “MOU”), which sets forth the principal terms on which the parties will negotiate a definitive agreement under which the Company would grant Meiji an exclusive license to its self-amplifying mRNA and lipid nanoparticle technologies for pandemic preparedness and response in Japan. Open the document at this passage
Nov 9
Investor event
Full CF Phase 2 data presentation guided for second quarter

Arcturus Therapeutics has guided a full data presentation for the complete fourth cohort of Phase 2 cystic fibrosis data for the second quarter in 27, with enrollment completing by year-end. A Phase 3 decision would trigger a $40 million contribution from Thermo Fisher. For its liver program, ARCT-2601 is expected to start its trial early next year, with top-line data in the second half of 27.

5 source passages
We've now guided a data presentation for the complete fourth cohort of Phase 2 data for the second quarter in 27 for our CF program. all we've said is we're completing enrollment by year-end We are motivated to proceed into Phase 3 or make that decision because it triggers an up-to-$40 million contribution from our Thermal Fisher deal. that would trigger a $40 million contribution for Thermo Fisher We call this ARCT-2601, and that program is starting its clinical trial, or at least we anticipate it to start early next year with some top-line data in the second half of 27. Open the document at this passage
Nov 5
Earnings call
ARCT2601 Phase 2 dosing planned next quarter

Arcturus plans Phase 2 dosing of ARCT2601 next quarter and expects top-line data in the second half of 2027. ARCT032 Phase 2 enrollment is expected by year-end, with full data planned for the second quarter of 2027.

2 source passages
Hello, and welcome, everyone, joining today's Arcturus Therapeutics third quarter 2026 earnings call. We expect a complete enrollment. In the ARCT032 Phase 2 study by year-end, present the full Phase 2 CF data in the second quarter of 2027, initiate Phase 2 dosing of ARCT2601 in the first quarter of 2027, and report top-line ARCT2601 data in the second half of 2027. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
CSL termination yields $16.8 million revenue and vaccine control

Arcturus Therapeutics Holdings Inc. recognized approximately $16.8 million of revenue after terminating its CSL Seqirus collaboration, regaining KOSTAIVE and other vaccine programs. Nine-month revenue fell $51.5 million, while cash and cash equivalents were $184.8 million at September 30, 2026.

Revenue $18.3M ▲ 6.7% Net loss $7.41M Diluted EPS -$0.26
Read from the MD&A section
5 source passages
The following is a discussion of the financial condition and results of operations of Arcturus Therapeutics Holdings Inc. for the three and nine months ended September 30, 2026. As a result of the termination, the Company regained strategic control of its vaccine portfolio, including KOSTAIVE® and its vaccine programs for seasonal influenza, pandemic influenza, respiratory syncytial virus (“RSV”) and Epstein-Barr virus (“EBV”), subject to ongoing arrangements with Meiji for the Northern Hemisphere 2026-2027 season. As a result of the termination, we recognized revenue of approximately $16.8 million during the third quarter of 2026. Revenue decreased by $51.5 million during the nine months ended September 30, 2026, as compared to the nine months ended September 30, 2025. As of September 30, 2026, the Company’s balance of cash and cash equivalents was $184.8 million. Open the document at this passage
Nov 5
Current report 8-K
Net loss narrows to $7.4 million; $12.0 million CSL Seqirus payment

Arcturus reported a net loss of $7.4 million for the three months ended September 30, 2026, compared with $13.4 million a year earlier, after recognizing the $12.0 million termination payment from CSL Seqirus. Cash and cash equivalents were $184.8 million at September 30, 2026. The company plans ARCT-032 Phase 2 data presentation in Q2 2027.

Financial results
5 source passages
Net loss was $7.4 million and $58.2 million for the three and nine months ended September 30, 2026 compared to a net loss of $13.4 million and $36.7 million for the three and nine months ended September 30, 2025 the $12.0 million payment received from CSL Seqirus under the termination and settlement agreement Cash and cash equivalents were $184.8 million as of September 30, 2026 ARCT-032 (CF) Phase 2 enrollment completion YE 2026; data presentation Q2 2027 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$30.51M
Trailing 12 months
Net income (TTM)
−$87.24M
Trailing 12 months
Revenue growth YoY
+6.7%
Year over year
Operating margin
-311.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$184.82M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.6%
Year over year · more shares
Price change (1Y)
+26.3%
Trailing year
Short interest
18.8%
Latest settlement · 7.4 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Arcturus reported meaningful biomarker activity and tolerability in ARCT-810, 38-fold greater LUNAR 2.0 potency in primates, ARCT-2601 development milestones, accelerated ARCT-032 enrollment and a cash runway through 2028. The quarter also featured lower nine-month revenue, a larger nine-month net loss, declining cash and uncertainty over a late-December study start.

Bullish
  • + ARCT-810 demonstrated meaningful biomarker activity and was generally safe and well tolerated in Phase 2.
  • + ARCT-032 Phase 2 enrollment accelerated following additional clinical-site activations in Israel and Turkey.
  • + LUNAR 2.0 demonstrated 38-fold greater potency in a non-human primate study.
  • + ARCT-2601 Phase 2 dosing is planned for Q1 2027, with top-line data expected in H2 2027.
  • + A decision to advance ARCT-032 into Phase 3 triggers significant Thermo Fisher contributions.
  • + The company has a cash runway of over two years through year-end 2028.
Bearish
  • − Cash and cash equivalents declined $46.1 million during the first nine months of 2026.
  • − Nine-month revenue was $23.3 million versus $74.8 million in the prior-year period.
  • − Nine-month net loss was $58.2 million versus $36.7 million in the prior-year period.
  • − A study start by late December was described as speculative.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −18%
below
Price vs 50-day avg −36%
below
RSI (14) 33
neutral
MACD trend Negative
52-week position 17%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −24%
trailing
6-month return −3%
trailing
YTD return +22%
this year
Relative strength +7%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $12 › 200d $9 — 50d above 200d
Institutional flow Accumulating
+14% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
18.77% of shares out · ▼ -0.9% MoM · 7.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
158 holders — mid 3-yr range
Squeeze score 72
high risk · 0–100
Fundamentals
Fair
Revenue growth −46%
Y/Y
EPS growth +20%
Y/Y
Free cash flow $-74.5M
Balance sheet $230.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 82%
annualized · 1-yr
Max drawdown −56%
past year
ATR 13.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−18% Bearish
Price vs 50-day avg
−36% Bearish
RSI (14)
33 Neutral
MACD trend
Negative Bearish
52-week position
17% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $12 › 200d $9 — 50d above 200d
Institutional flow Accumulating
+14% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
18.77% of shares out · ▼ -0.9% MoM · 7.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
158 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6 Now $7 · 17% Range high $17
vs 200-day avg -18% vs 50-day avg -36%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ARCT
Arcturus Therapeutics Holdings Inc.
this stock
$214.73M +21.5% -46.1% — 18.8%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
158
% held
87.8%
Net QoQ
+288.6K sh
Top holder
ARK Investment Management…
Held Float
View
Held by Funds
Fund positions
149
View
Short & Settlement
Short Interest Falling
Shares short
5.4M
Days to cover
7.4d
Change
-50.5K sh
View
Short Volume
Short vol %
55%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
992.0K
Value
$11.2M
As of
Oct 16, 2026
View
Off-Exchange
Off-exchange %
38.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$82.0M
Net income (FY)
$-65.8M
EPS diluted
$-2.40
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 16, 2026
This year
19

Arcturus sold 2,466,395 shares to Meiji for $50.0 million at an 80% premium, alongside an ARCT-154 license and a nonbinding MOU covering pandemic preparedness in Japan.

View
Proposed Sales
Value
$249.1K
Shares
12.0K
Filed
Oct 15, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
Arcturus Therapeutics Announces $…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
ARCT -10.9% -24.3% -2.6% -32.5% +21.5%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -2.3% -15.1% +6.6% -23.7% +20.4%
Key facts CIK 1768224 CUSIP 03969T109 13F (30d) 172 filings 143 filers Visit website Investor relations